Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD

NCT01655004 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Breast Carcinoma

Interventions

DRUG: Exemestane

Sponsor

National University Hospital, Singapore